dc.contributor.author | Lophatananon, A | |
dc.contributor.author | Stewart-Brown, S | |
dc.contributor.author | Kote-Jarai, Z | |
dc.contributor.author | Olama, AAA | |
dc.contributor.author | Garcia, SB | |
dc.contributor.author | Neal, DE | |
dc.contributor.author | Hamdy, FC | |
dc.contributor.author | Donovan, JL | |
dc.contributor.author | Giles, GG | |
dc.contributor.author | Fitzgerald, LM | |
dc.contributor.author | Southey, MC | |
dc.contributor.author | Pharoah, P | |
dc.contributor.author | Pashayan, N | |
dc.contributor.author | Gronberg, H | |
dc.contributor.author | Wiklund, F | |
dc.contributor.author | Aly, M | |
dc.contributor.author | Stanford, JL | |
dc.contributor.author | Brenner, H | |
dc.contributor.author | Dieffenbach, AK | |
dc.contributor.author | Arndt, V | |
dc.contributor.author | Park, JY | |
dc.contributor.author | Lin, H-Y | |
dc.contributor.author | Sellers, T | |
dc.contributor.author | Slavov, C | |
dc.contributor.author | Kaneva, R | |
dc.contributor.author | Mitev, V | |
dc.contributor.author | Batra, J | |
dc.contributor.author | Spurdle, A | |
dc.contributor.author | Clements, JA | |
dc.contributor.author | APCB BioResource, | |
dc.contributor.author | PRACTICAL consortium, | |
dc.contributor.author | Easton, D | |
dc.contributor.author | Eeles, RA | |
dc.contributor.author | Muir, K | |
dc.date.accessioned | 2017-11-01T16:02:11Z | |
dc.date.issued | 2017-08-22 | |
dc.identifier.citation | British journal of cancer, 2017, 117 (5), pp. 734 - 743 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/894 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2017.231 | |
dc.description.abstract | BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions. RESULTS: The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group. CONCLUSIONS: There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures. | |
dc.format | Print-Electronic | |
dc.format.extent | 734 - 743 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | APCB BioResource | |
dc.subject | PRACTICAL consortium | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Body Height | |
dc.subject | Risk Assessment | |
dc.subject | Case-Control Studies | |
dc.subject | Polymorphism, Single Nucleotide | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Male | |
dc.subject | Neoplasm Grading | |
dc.subject | Gene-Environment Interaction | |
dc.title | Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-06-23 | |
rioxxterms.versionofrecord | 10.1038/bjc.2017.231 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 117 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Oncogenetics | |
dc.contributor.icrauthor | Kote-Jarai, Zsofia | |
dc.contributor.icrauthor | Eeles, Rosalind | |